TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

Core Insights - TransCode Therapeutics, Inc. announced preclinical research supporting its lead candidate TTX-MC138 for glioblastoma multiforme (GBM) treatment, published in the Journal of Functional Biomaterials [1][2] Group 1: Research Findings - Glioblastoma is identified as the most aggressive primary brain cancer, with a median survival of under two years despite current treatments [2] - The study demonstrated that TTX-MC138 can be delivered to human GBM tumors in murine models via intravenous injection, leading to sustained target engagement and a five-fold increase in apoptotic activity in tumors [3][9] - Treatment with TTX-MC138 resulted in a statistically significant increase in survival rates in the studied models [3][9] Group 2: Development and Future Plans - The findings support the capability of TransCode's TTX platform to deliver antisense oligonucleotides (ASOs) to brain tumors, overcoming delivery barriers such as nucleic acid degradation [4] - TTX-MC138 has completed IND enabling studies, pharmacokinetics, biodistribution, and toxicity studies, showing safety in Phase I clinical trials for non-CNS cancers, paving the way for future clinical evaluations in GBM patients [4][6] - A Phase 2a clinical trial for TTX-MC138 is anticipated to begin in the first half of 2026, highlighting the translational relevance of this therapeutic approach [6] Group 3: Company Overview - TransCode Therapeutics is focused on immuno-oncology and RNA therapeutics for high-risk and advanced cancers, with TTX-MC138 targeting metastatic tumors that overexpress microRNA-10b [7] - The company has a portfolio of first-in-class therapeutic candidates aimed at mobilizing the immune system to combat cancer cells [7]